Technical Program
Technical Program for AccBio 2023
To View Abstracts for AccBio Conference please CLICK HERE
| Start Time | End Time | |
| September 6, 2023 | All Eastern Standard Time | |
| Day 1 | ||
| 1:00 PM | 4:00 PM | Registration |
| 2:00 PM | 2:10 PM | Conference Introduction by Chairs: Ganesh Vedantham, Biomarin & Glen Bolton, Amgen |
| 2:10 PM | 2:50 PM | KEYNOTE: In pursuit of Africa’s health Security: Building strategic capabilities in South Africa to facilitate broader access to vaccines and biologics on the continent, Rachel Chikwamba, CSIR, |
| 2:50 PM | 3:20 PM | Afternoon Coffee Break Sponsored by Takeda |
| 3:20 PM | 4:00 PM | KEYNOTE: Answering pressing questions about Gene Therapy to enable transformative medicine, Kevin Eggan, BioMarin, |
| 4:00 PM | 5:00 PM | Poster Session hosted by NIIMBL and Cocktail Reception hosted by 3M |
| Start Time | End Time | |
| 9/7/2023 | All Eastern Standard Time | |
| Day 2 | ||
| 7:00 AM | 4:00 PM | Registration |
| 7:30 AM | 8:00 AM | Breakfast |
| 8:00 AM | 8:10 AM | Day 2 Welcome and Introduction by Chairs: Ganesh Vedantham, Biomarin & Glen Bolton, Amgen |
| 8:10 AM | 8:50 AM | KEYNOTE: Multispecificity – The Future of Molecular Medicines, Raymond Deshaies, Amgen |
| 8:50 AM | 9:00 AM | Stretch Break |
| 9:00 AM | 12:45 PM | Session 1: Enduring Lessions Learned from the Pandemic |
| 9:00 AM | 9:05 AM | Introduction by Session Chairs: Greg Naugle, GSK and Jeff Salm, Pfizer |
| 9:05 AM | 9:30 AM | CMC Strategies for Accelerated Development of Complex Biologics for Unmet Medical Needs from an Analytical Perspective, Qian Wang, Pfizer, |
| 9:30 AM | 9:55 AM | Enduring effects from the pandemic: Innovation in drug delivery, Rubi Burlage, Merck |
| 9:55 AM | 10:20 AM | Process Validation in a Pandemic, David Robbins, AstraZeneca |
| 10:20 AM | 10:50 AM | Morning Coffee Break |
| 10:50 AM | 11:15 AM | Lessons in Speed from the Pandemic: Preclinical Development and Company Collaboration, John Mattila, Regeneron |
| 11:15 AM | 11:40 AM | Collaboration with a competitor: A pandemic success story between Lilly and Amgen, Myrta Atiles, Amgen |
| 11:40 AM | 12:40 PM | Q&A Panel Discussion |
| 12:40 PM | 12:45 PM | Closing Remarks by Session Chair: Greg Naugle, GSK |
| 12:45 PM | 1:45 PM | Lunch |
| 1:45 PM | 5:40 PM | Session 2: Accelerating Development Using Predictive Technologies |
| 1:45 PM | 1:50 PM | Introduction by Session Chairs: Rohini Deshpande, Amgen and Raghu Shivappa, Takeda |
| 1:50 PM | 2:10 PM | Using Stability Prior Knowledge from ‘Like-molecules’ to Establish Shelf-life and Accelerate Product Development, Barbara Rellahan, Amgen |
| 2:10 PM | 2:30 PM | Digital Thread Centric IOT Data to Break Down Data Silos, Shanti Chari, Landmark Bio |
| 2:30 PM | 2:50 PM | Research in-silico modeling/predictions and experimental work, Trevor Swartz, Genentech |
| 2:50 PM | 3:10 PM | Transforming Upstream Process Development through Implementation of Predictive Models, Jackie Gonzalez, Takeda |
| 3:10 PM | 3:30 PM | Centralizing Lab and Process Data -- Challenges for Connecting and Modeling Bioprocessing Data, Jason Hirshman, Uncountable |
| 3:30 PM | 4:00 PM | Afternoon Coffee Break Sponsored by Lilly |
| 4:00 PM | 4:20 PM | Implementation of an Online PAT Co-Laboratory for Accelerating Process Development, Katrina Janiszewski, Takeda |
| 4:20 PM | 4:40 PM | Smart Process Analytics for the End-to-End Batch Manufacturing of Monoclonal Antibodies, Richard Braatz, MIT |
| 4:40 PM | 5:40 PM | Q&A Panel Discussion |
| 5:40 PM | 6:40 PM | Cocktail Reception Sponsored by Pfizer |
| Start Time | End Time | |
| 9/8/2023 | All Eastern Standard Time | |
| Day 3 | ||
| 7:00 AM | 3:00 PM | Registration |
| 7:30 AM | 8:00 AM | Breakfast |
| 8:00 AM | 8:10 AM | Day 3 Welcome and Introduction by Chairs: Ganesh Vedantham, Biomarin & Glen Bolton, Amgen |
| 8:10 AM | 8:50 AM | Keynote Speaker 4: Development speed: what's different for novel modalities, Alison Moore, Allogene |
| 8:50 AM | 9:00 AM | Stretch Break |
| 9:00 AM | 10:15 AM | Round Table 1 Make vs Buy; Small Footprint Manufacturing, Global Accessibility Moderated by Brian Kelley; Panelists: Dana Andersen (Denali), Todd Ireland (Just), Andy Lin (GNE), Nicole Murphy (Biogen), Hari Pujar (Flagship) |
| 10:15 AM | 10:45 AM | Morning Coffee Break |
| 10:45 AM | 12:00 PM | Round table 2 RM Supply Risk Management / Second Sourcing Strategies Moderated by: Patrick Gammel; Panlists: |
| 12:00 PM | 1:00 PM | Lunch |
| 1:00 PM | 4:30 PM | Session 3: Fast to Patients: Beyond mAB to New Modailities |
| 1:00 PM | 1:05 PM | Introduction by Session Chair: Greg Nyberg, Landmark Bio & Cleo Salisbury, Genentech |
| 1:05 PM | 1:25 PM | Making the move from antibody therapeutics to gene therapy: applying monoclonal antibody learnings to adeno-associated virus vector bioprocessing, Andrew Tustian, Regeneron |
| 1:25 PM | 1:45 PM | Fast to Tox for a platform AAV vector and how to follow it, Terrence Dobrowsky, Biogen |
| 1:45 PM | 2:05 PM | Platform-Based Approaches to Streamline Vaccine Development and Validation, Brenda Carillo Conde, Pfizer |
| 2:05 PM | 2:35 PM | Afternoon Coffee Break |
| 2:35 PM | 2:55 PM | New therapeutic modalities and Moore’s Law, Hari Pujar, Flagship |
| 2:55 PM | 3:15 PM | Accelerated Manufacturing of LVV based CAR-T Products, Divya Varun, BMS |
| 3:15 PM | 3:35 PM | Regenerative medicine products and the inherent polypharmacology of cell therapy, Derek Adams, Stellular Bio |
| 3:35 PM | 4:15 PM | Q&A Panel Discussion: (platform vs toolbox vs free for all) |
| 4:15 PM | 4:30 PM | Closing by the Chairs: Ganesh Vedantham, Biomarin & Glen Bolton, Amgen |
